<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00622375</url>
  </required_header>
  <id_info>
    <org_study_id>MPPK1003</org_study_id>
    <nct_id>NCT00622375</nct_id>
  </id_info>
  <brief_title>PK Study of Encapsulated Mesalamine Granules in Healthy Volunteers</brief_title>
  <official_title>A Phase I, Single- And Multiple-Dose, Relative Bioavailability and Pharmacokinetic Study of Encapsulated Mesalamine Granules Administered Orally to Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch Health Americas, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch Health Americas, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study is being conducted to evaluate the relative bioavailability and single- and&#xD;
      multiple-dose pharmacokinetics of encapsulated mesalamine granules(eMG) in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Individual pharmacokinetic parameters for mesalamine and its metabolites will be summarized with descriptive statistics</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mesalamine</intervention_name>
    <description>encapsulated mesalamine granules</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject is Male, or female of Non-childbearing potentia.l&#xD;
&#xD;
          -  The subject is female of childbearing potential, who has a negative serum pregnancy&#xD;
             test at screen and agrees to using appropriate birth control.&#xD;
&#xD;
          -  The subject is between the ages of 18 and 45 years.&#xD;
&#xD;
          -  The subject has a body mass index (BMI) between 18 and 32 kg/m2 (weight/[height]).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject is seropositive for human immunodeficiency virus (HIV),hepatitis B surface&#xD;
             antigen, and/or hepatitis C virus.&#xD;
&#xD;
          -  The subject has any clinically significant medical, social, or emotional problem.&#xD;
&#xD;
          -  The subject is pregnant or lactating&#xD;
&#xD;
          -  The subject has a history of clinically significant renal, hepatic,endocrine,&#xD;
             oncological,gastrointestinal, or cardiovascular disease or a history of epilepsy,&#xD;
             asthma, diabetes mellitus, psychosis, glaucoma, or severe head injury.&#xD;
&#xD;
          -  The subject is currently receiving mesalamine or aspirin containing products&#xD;
&#xD;
          -  The subject has a history of viral, bacterial, or fungal infection within 4 weeks of&#xD;
             screening.&#xD;
&#xD;
          -  The subject has an acute illness within 1 week of study-drug administration.&#xD;
&#xD;
          -  The subject has an abnormal nutritional status, including unconventional,&#xD;
             alternative,and abnormal diets; excessive or unusual vitamin intake; malabsorption;&#xD;
             psychological eating disorders; difficulty swallowing medication; significant recent&#xD;
             weight change; etc.&#xD;
&#xD;
          -  The subject has clinically significant allergies.&#xD;
&#xD;
          -  The subject has a hypersensitivity or allergy to mesalamine or other salicylate.&#xD;
&#xD;
          -  The subject has known or suspected alcohol abuse or illicit drug use within the past&#xD;
             year&#xD;
&#xD;
          -  The subject has used tobacco (or nicotine products) during the 6 months prior to&#xD;
             screening&#xD;
&#xD;
          -  The subject has participated in an investigational drug study within the 30 days&#xD;
             before receiving study drug&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Audrey Shaw, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Bausch Health Americas, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>February 14, 2008</study_first_submitted>
  <study_first_submitted_qc>February 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2008</study_first_posted>
  <last_update_submitted>November 14, 2019</last_update_submitted>
  <last_update_submitted_qc>November 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetic study</keyword>
  <keyword>Healthy subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesalamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

